← Back to Search

Deep Learning Model for Cardiac Amyloidosis

N/A
Recruiting
Led By Timothy J. Poterucha, MD
Research Sponsored by Timothy Poterucha
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 50 years
Be older than 18 years old
Must not have
Active malignancy or non-amyloid disease with expected survival of less than 1 year
Primary amyloidosis (AL) or secondary amyloidosis (AA)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year after identification
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to test a computer model that can identify patients with a specific type of heart condition called cardiac amyloidosis. The model uses data from heart ultrasounds, ECGs, and

Who is the study for?
This trial is for individuals who may have cardiac amyloidosis, a heart condition that can lead to heart failure. It's aimed at those who haven't been diagnosed yet but are suspected of having the disease based on certain heart tests and clinical factors.
What is being tested?
The study is testing a deep learning model designed to spot signs of cardiac amyloidosis using data from echocardiograms, ECGs, and patient history. Participants identified as high-risk by this model will be invited for further tests to confirm diagnosis.
What are the potential side effects?
Since this trial involves diagnostic procedures rather than medication or invasive treatments, traditional side effects are not applicable. However, there may be minimal risks associated with additional diagnostic testing.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 50 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a life expectancy of more than 1 year despite my cancer.
Select...
My condition is diagnosed as primary or secondary amyloidosis.
Select...
I have had a liver or heart transplant.
Select...
I do not have any conditions like a stroke that would stop me from joining the study.
Select...
I live in a nursing home.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year after identification
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year after identification for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rate of Cardiac Amyloidosis Diagnosis

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Intervention ArmExperimental Treatment1 Intervention
Patients who are identified by the deep learning model as being at high risk for undiagnosed cardiac amyloidosis who are enrolled in the study.

Find a Location

Who is running the clinical trial?

PfizerIndustry Sponsor
4,655 Previous Clinical Trials
17,746,158 Total Patients Enrolled
1 Trials studying Cardiac Amyloidosis
424 Patients Enrolled for Cardiac Amyloidosis
Eidos Therapeutics, a BridgeBio companyIndustry Sponsor
11 Previous Clinical Trials
2,317 Total Patients Enrolled
Timothy PoteruchaLead Sponsor
~67 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top